A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.

Richard D. Kim, Aung Naing, Sara Ferrando‐Martínez et al.|Journal of Clinical Oncology|2024

Cited by 3